HK Stock Market Move | JIASHILI GP (01285) surged over 17% in late trading, expecting a year-on-year increase in net profit of about 640% to 663% for the first half of the year.
Jia Shi Li Group (01285) surged significantly today, closing with an increase of over 17% at the end of trading.
JIASHILI GP (01285) jumped significantly today with a gap up, expanding its rise to over 17% in the late session. As of the time of this report, it is up 16.8%, priced at HKD 1.46, with a trading volume of HKD 3.3267 million.
In terms of news, JIASHILI GP announced a positive profit forecast last night, expecting its net profit for the first half of this year to be approximately RMB 58.9 million to about RMB 61 million, representing an increase of about 640% to 663% year-on-year. This is mainly attributed to an increase in sales revenue of about RMB 60.3 million during the period; the continuous implementation of lean management strategies involving cost reduction, efficiency enhancement, optimization of management, and technological transformation led to a decrease in administrative and sales expenses of about RMB 25.2 million year-on-year; the stability of the global commodity market and a decline in raw material costs contributed to a year-on-year increase in gross profit of about RMB 21.7 million.
Related Articles
Bank of America Securities: Downgraded HAIDILAO (06862) target price to HKD 12.3, half-year results generally in line with expectations.

Lyon: Raises the target price of REMEGEN (09995) to HK$144.8, maintains "Outperform" rating.

Lyon: Maintain the "Outperform Market" rating for CHINARES PHARMA (03320), with a target price revised down to HKD 6.5.
Bank of America Securities: Downgraded HAIDILAO (06862) target price to HKD 12.3, half-year results generally in line with expectations.
Lyon: Raises the target price of REMEGEN (09995) to HK$144.8, maintains "Outperform" rating.

Lyon: Maintain the "Outperform Market" rating for CHINARES PHARMA (03320), with a target price revised down to HKD 6.5.

RECOMMEND





